Understanding PDE2A: Potential Drug Target and Biomarker (G5138)

Target Name: PDE2A

NCBI ID: G5138

PDE2A

Understanding PDE2A: Potential Drug Target and Biomarker

The protein encoded by the gene PDE2A (Proteolytic-Dipeptidase 2A) is a member of the superfamily of cysteine 鈥嬧?媝rotease family, which includes a variety of enzymes involved in protein degradation. PDE2A is a 21-kDa protein that is expressed in many tissues and cells , including brain, heart, liver, and muscle. It is involved in the regulation of protein function and has been implicated in a number of cellular processes.

PDE2A variants

PDE2A has several variants, includingPDE2A variant 1, which is a missense variant that is associated with a number of cellular processes. PDE2A variant 1 has been shown to have altered cellular signaling pathways and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug targeting

One potential approach to targeting PDE2A is to use small molecules that can inhibit its activity. This approach is based on the idea that by disrupting the function of PDE2A, it may be possible to treat a variety of diseases that are caused by the over-activity or dysfunction of this protein.

Studies have shown that PDE2A is involved in a number of cellular signaling pathways, including the regulation of cell adhesion, the production of reactive oxygen species (ROS), and the regulation of protein function. Therefore, small molecules that can inhibit PDE2A activity may have a wide range of potential therapeutic applications.

One class of small molecules that have been shown to inhibit PDE2A activity is called IDEs (Inhibitors of DNA-Binding Enzymes). IDEs work by binding to specific DNA-binding domains within PDE2A and disrupt its activity. This class of drugs has been shown to be effective in a number of diseases, including neurodegenerative disorders and cancer.

Another class of small molecules that have been shown to inhibit PDE2A activity are the benzimidazoles, which are a type of small molecule that can inhibit the activity of a variety of enzymes, including PDE2A. These drugs have been shown to be effective in a number of diseases, including neurodegenerative disorders and cancer.

Biomarker

PDE2A is also an attractive biomarker for a variety of diseases, including cancer. This is because the activity of PDE2A is often altered in cancer cells, and it can be used as a target for drug development.

For example, it has been shown that PDE2A is often overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. This overexpression is thought to contribute to the development and progression of these diseases. Therefore, inhibiting PDE2A activity may be an effective way to treat these cancers.

Conclusion

PDE2A is a protein that is involved in a number of cellular processes and has been implicated in a variety of diseases. In addition, PDE2A is also a potential drug target, as small molecules that can inhibit its activity may have a wide range of therapeutic applications . Further research is needed to fully understand the role of PDE2A in disease and to develop effective treatments.

Protein Name: Phosphodiesterase 2A

Functions: cGMP-activated cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes (PubMed:9210593, PubMed:29392776, PubMed:15938621). Has a higher efficiency with cGMP compared to cAMP (PubMed:15938621). Plays a role in cell growth and migration (PubMed:24705027)

The "PDE2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDE2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets